Publications 2019

Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019) Preclinical evaluation of the pan-FGFR inhibitor LY2874455 in FRS2-amplified liposarcoma. Special Issue “Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor: Cells 2019, 8(2), 189; PDF (Open Access) DOI:10.3390/cells8020189  

Myklebost O (Ed) Genomsekvensering for bedre persontilpasning av kreftbehandling. (100 p report from the Cancer Genomics Consortium in Norwegian) Jan 2019 pdf 

Publications 2018

Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O,Knappskog S, Lønning PE (2018) Patterns of genomic evolution in advanced melanoma. Nature Comm DOI: 10.1038/s41467-018-05063-1  

Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E (2018) Preclinical evaluation of vemurafenib as therapy for BRAFV600E mutated sarcomas Int J Mol Sci DOI:10.3390/ijms19040969 

Kresse SK, Namløs HM, Lorenz S, Berner JM, Ola Myklebost O, Bjerkehagen B, Meza-Zepeda LA(2018) Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples. PLoS One https://doi.org/10.1371/journal.pone.0197456 

Nakken S, Fournous G, Vodak D, Aasheim B, Myklebost O, Hovig E (2017) Personal Cancer Genome Reporter: Variant Interpretation Report For Precision Oncology. Bioinformatics 1–3 doi:10.1093/bioinformatics/btx817 

Namløs H, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA(2018) Non-invasive detection of ctDNA reveals intratumour heterogeneity and is significantly associated with aggressive GIST Mol Cancer Ther  10.1158/1535-7163.MCT-18-0174

Serguienko A, Wang MY, Myklebost O(2018) Real-time vital mineralization detection and quantification during in vitro osteoblast differentiation. Biological Procedures Online (2018) 20:14 DOI: 10.1186/s12575-018-0079-4 

Strauss SJ, Anninga J, Baglio B, Baumhoer D, Behjati S, Bielack S, Boye K, Broto JM, Cleton‑Jansen AM, Degasperi A, Evans A, Fagioli F, Fiocco M, Gaspar N, Heymann D, Hindi N, Lancia C, Myklebost O, Nathrath M, Redini F, Scotlandi K, Tirtei E, Vanden Eynden M, Whelan J (2018) Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma Clin Sarcoma Res 8:17 DOI:10.1186/s13569-018-0103-0 

Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018) Sample-Index Misassignment Impacts Tumour Exome Sequencing Sci. Rep. DOI:10.1038/s41598-018-23563-4 

 

Publications 2017

Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, Cooke SL, Davies H, Mifsud W, Lidgren M, Martin S, Latimer C, Maddison M, Butler AP, Teague JW, Pillay N, Shlien A, McDermott U, Futreal PA, Baumhoer D, Zaikova O, Bjerkehagen B, Myklebost O, Amary MF, Tirabosco R, Van Loo P, Stratton MR, Flanagan AM, Campbell PJ (2017) Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma Nature Communications 23:15936 doi: 10.1038/ncomms15936

Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017) Multi-omics of 34 colorectal cancer cell lines – a resource for biomedical studies Mol Cancer 16:116 doi: 10.1186/s12943-017-0691-y

Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Munthe E, Myklebost O (2017) Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b Sci Rep DOI:10.1038/s41598-017-10189-1

Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017) High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival. Int J Cancer 141:184-190 doi: 10.1002/ijc.30726

Nakken S, Fournous G, Vodak D, Aasheim B, Myklebost O, Hovig E (2017) Personal Cancer Genome Reporter: Variant Interpretation Report For Precision Oncology. Bioinformatics 1–3 doi:10.1093/bioinformatics/btx817

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017) Monitoring of Multiple Myeloma by quantification of recurrent mutations in serum Haematologica 102:1266-1272 doi: 10.3324/haematol.2016.160564

Serguienko A, Hanes R,Grad I, Wang MY, Munthe E, Myklebost O (2017) PP2A regulatory subunit B55γ is a gatekeeper of osteoblast maturation and lineage maintenance Stem Cells Devel 26: 1375-1383 doi: 10.1089/scd.2017.0129

Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017) Multilevel genomics of colorectal cancers with microsatellite instability – clinical impact of JAK1 mutations and consensus molecular subtype 1 Genome Medicine 9:46 doi: 10.1186/s13073-017-0434-0

Publications 2016

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall L, Judson I, Seddon B, Cambell IG, Young MA, Sarin R, Blay JY, O’Donoghue SI, Thomas D (2016Novel monogenic and polygenic determinants of sarcoma risk: an international study of 1162 families Lancet Oncology 17:1261–1271 PDF

Barøy T, Chilamakuri CSR, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA (2016) Genome analysis of osteosarcoma progression samples identifies FGFR1 overexpression as a potential treatment target and CHM as a candidate tumor suppressor gene Plos One 11: e0163859 DOI:10.1371/journal.pone.0163859

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O; Børresen-Dale AL, Brustugun OT, Helland Å (2016) TP53 mutation spectrum in smokers and never smoking lung cancer patients Frontiers in Genetics 7:85.

Hanes, R., I. Grad, S. Lorenz, E. W. Stratford, E. Munthe, C. C. S. Reddy, L. A. Meza-Zepeda and O. Myklebost(2016). Amplified FRS2 identified as a target for treatment of dedifferentiated liposarcoma by genome sequencing and functional validation. Oncotarget 7:54583.

Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JV, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GH, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS (2016) The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. Clin Sarcoma Res. 16;6:3

Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2016) Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report BMC Cancer In press

Sandhu V, Wedge DC, Lothe IMB, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børressen-Dale AL, Ikdahl T, Van Loo P, Nord S (2016) The genomic landscape of pancreatic and periampullary adenocarcinoma. Cancer Research 76(17); 1–11

Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T (2016)
VOLIN and KJON-Two novel hyperdiploid myeloma cell lines Genes Chromosomes Cancer, 55 (11), 890-901
PubMed 27311012

Publications 2015

Budin-Ljøsne I, Bentzen HB, Solbakk JH, Myklebost O (2015) Genome sequencing in research requires a new approach to consent Tidskr Nor Legeforening PDF

Chymkowitch P, Nguéa P A, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM (2015) Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes Genome Res, 25 (6), 897-906 PubMed 25800674

Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015) Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biol, 16, 7 PubMed 25650807

Ju YS, Tubio JMC, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A,Gerstung M, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Ta M, Lee M, van’t Veer LJ, Tan BKT, Aparicio S, Span PN, Martens JWM, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PM, Stratton MR (2015) Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells Genome Res 25:814-24. doi: 10.1101/gr.190470.115

Kanojia D, Nagata Y, Garg M, Lee DH, Anand MT, Christoph H, Klein HU, Said JW, Doan NB, Mohith S, Gunasekar S, Myklebost O, Yang H, Dugas M, Meza‐Zepeda LA, Silberman AW, Forscher C, Ogawa S, Koeffler HP (2015) Genomic landscape of liposarcoma Oncotarget DOI: 10.18632/oncotarget.6464

Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GOS, Skotheim RI, Lothe RA, Tarpey P, Campbell P, Flanagan A, Meza-Zepeda LA, Myklebost O (2015) Unscrambling the genomic chaos of osteosarcoma reveals recurrent rearrangements and frequent novel TP53 aberrations Oncotarget DOI: 10.18632/oncotarget.6567

Myklebost O (2015) Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls (Review) Personalized Medicine 12:593-602 PDF

Myklebost O (2015) Norwegian Cancer Genomics Consortium, a platform for research on personalized cancer medicine in a public health system. Drug Discovery Today: Special issue on Stratified Medicine doi:10.1016/j.drudis.2015.10.003

Naderi EH, Ugland H, Myklebost O, Sandnes DL, Torgersen ML, Josefsen D, Ellen Ruud E, Naderi S, Blomhoff HK (2015) Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death, Mol Cancer in press doi:10.1186/s12943-014-0278-9

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost, Ola, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E,Sandvik A, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015) Clinical and biological implications of BRAF V600E mutation in multiple myeloma. Blood Cancer J doi:  10.1038/bcj.2015.24

Safavi S, Järnum S, Vannas C, Udane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stock ES, Ståhlberg A, Åman P (2015) HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget  PDF

Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Ola Myklebost O, Munthe E (2015) Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA Oncotarget 6(4): 2451–2465

Publications 2014

Anninga JK, Cleton-Jansen AM, Hassan B, Amary MF, Baumhoer D, Blay JY, Brugieres L, Ferrari S, Jürgens H, Kempf-Bielack B, Kovar H, Myklebost O, Nathrath M, Picci P, Riegman P, Schilham MW, Soliman R, Stark DP, Strauss A, Sydes M, Tarpey P, Thomas D, Whelan J, Wilhelm M, Zamzam M, Gelderblom H, Bielack SS (2014Workshop Report on the 2nd Joint ENCCA/EuroSARC European Bone Sarcoma Network Meeting: Integration of Clinical Trials with Tumour BiologyClinical Sarcoma Research 4:4 PDF

Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA (2014Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma modelMolecular Cancer 13:93 doi:10.1186/1476-4598-13-93 PDF

Chilamakuri CSR, Lorenz S, Madoui MA, Vodák DA, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA (2014Performance Comparison of four exome capturing systems for deep sequencing. BMC Genomics PDF

Garsed DW, Marshall OJ, Corbin VDA, Hsu A, di Stefano L, Schröder J, Li J, Feng ZP, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O, Meza-Zepeda LA, Holloway AJ, Pedeutour F, Choo KHA, Damore MA, Deans AJ, Papenfuss AT, Thomas DM (2014) Architecture and Evolution of a Cancer Neochromosome, Cancer Cell 26:653-667 PDF

  • Comment in Cancer Cell by Waterfall and Meltzer PDF

Håkelien AM, Bryne JC, Harstad KG, Lorenz S, Paulsen J, Sun J, Mikkelsen TS, Myklebost O, Meza Zepeda LA(2014) The regulatory landscape of osteogenic differentiationStem Cells PDF

Skårn M, Noordhuis P, Wang MY, Veuger MJT, Kresse SH, Egeland EV, Micci F, Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S, Haraldsen G, Kvalheim G, Meza-Zepeda LA, Myklebost O (2014) Generation and characterisation of an immortalised human bone marrow derived mesenchymal stromal cell lineStem Cells and Development PDF

These cells are now available commercially from Applied Biological Materials Inc

Stratford EW, Myklebost O (2014TRAP1 is a novel interaction partner of PML, localised with PML in nuclear bodies and relocating with PML to the cytoplasm following stressAnnual research and review in biology 3:36-46 PDF

Tran D, Verma K, Ward K, Diaz D, Kataria E, Torabi A, Almeida A, Malfoy B, Stratford EW, Mitchell DC, Bryan BA (2014) Functional Genomics Analysis Reveals a MYC Signature Associated with a Poor Clinical Prognosis in Liposarcomas Am J Pathol In press doi:10.1016/j.ajpath.2014.11.024

Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O’Meara S, Andreson E, Maddison M, Gamble S, ICGC Breast Cancer Group, ICGC Bone Cancer Group, ICGC Prostate Cancer Group, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, van’t Veer L, Caldas C, Desmedt C, Sotiriou C, Aparicio A, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL,van de Vijver M, Vincent-Salomon A, van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ (2014Extensive transduction of non-repetitive DNA mediated by L1 retrotransposition in cancer genomes Science 345 no. 6196 DOI: 10.1126/science.1251343

Wennerström AB, Lothe IMB, Sandhu V, Kure E, Myklebost O, Munthe E (2014Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell linesPLoS One 10.1371/journal.pone.0103873

Publications 2013

Behjati S, Tarpey PS, Presneau N, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gudem G, Davies H, Nik-Zainal S, Gamble J, Hardy C, Latimer C, Maddison M, Martin S, McLaren S, Mudie L, O’Meara S, Robinson B, Butler A, Teague JW, Kathri B, Halai D, Myklebost O, Baumhoer D, Jundt G, Tirabosco R, Amary F, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM (2013) Distinct H3F3A and H3F3B driver variants define chondroblastoma and giant cell tumour of bone Nat Genet45:1479-82. doi: 10.1038/ng.2814

Bianchini L, Birtwisle L, Saâda E, Bazin A, Long E, Roussel JF, Michiels JF, Forest F, Dani C, Myklebost O, Birtwisle-Peyrottes I, Pedeutour F. (2013) Identification of PPAP2B as a novel recurrent translocation partner gene of HMGA2 in lipomas. Genes Chromosomes Cancer doi: 10.1002/gcc.22055 PDF

Doorn J, Hugo Fernandes H, Lee B, van de Peppel J, van Leeuwen JPTM, De Vries MR, Aref Z, Quax PHA, Myklebost O, Saris D, van Blitterswijk CA, de Boer J. (2013) A small molecule approach to engineering vascularized tissue. Biomaterials  34 (12), 3053-63 PDF

Kuijjer ML, Peterse EFP, van den Akker BEWM, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PCW, Cleton-Jansen AM (2013) IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma BMC Cancer 13:245 doi:10.1186/1471-2407-13-245

Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA Myklebost O (2013) Functional characterization of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes Br. J. Cancer in press PDF

Nome T, Thomassen GOS, Bakken AC, Bruun J, Ahlquist T, Lorenz S, Sun J, Barros-Silva JD, Myklebost O, Teixeira M, Meza-Zepeda LA, Lothe RA, Skotheim RI (2013) Common fusion transcripts identified in colorectal cancer cell lines by high throughput RNA sequencing. Translational Oncology 6:546–553 PDF

Qu S, Olafsrud SM, Meza-Zepeda LA, Saatcioglu F (2013) Rapid gene expression changes in peripheral blood lymphocytes upon practice of a comprehensive yoga program PLoS One, 8 (4), e61910

Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, Grasmo-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W, Langmoen IA (2013) Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome Experimental Cell ResearchPDF

Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K (2013) Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer PLoS One, 8 (6), e66165


Stratford EW
, Bostad M, Castro R, Skarpend E, Berg K, Høgset A, Myklebost O, Selbo PK (2013) Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity Biochim Biophys Acta 1830:4235-43. doi: 10.1016/j.bbagen.2013.04.033s

Stratford EW, Daffinrud J, Munthe E, Castro R, Waaler J, Krauss S, Myklebost O (2013) The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Medicine doi:10.1002/cam4.170

Skårn M, Barøy T, Stratford EW, Myklebost O (2013) Epigenetic regulation and functional characterization of mir-142 in mesenchymal cells PLoS One  Link

Thomas D, Myklebost O, Meza-Zepeda LA (2013) Research in Well-Differentiated and Dedifferentiated Liposarcoma ESUN – A Periodical for the Sarcoma Community, Volume 10, Number 1 Link

Wang P, Gao1 Q, Suo Z, Munthe E, Solberg S, Ma L, Wang MY, Westerdaal NAC, Kvalheim G, Gaudernack G (2013) Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines PLoS One in press

Publications 2012

Bjørnstad LG, Meza TJ, Otterlei M, Olafsrud SM, Meza-Zepeda LA, Falnes PØ (2012Human ALKBH4 interacts with proteins associated with transcription PLoS One, 7 (11), e49045 PubMed 23145062

Chymkowitch P, Eldholm V, Lorenz S, Zimmermann C, Lindvall J, Bjørås M, Meza-Zepeda LA, Enserink JM (2012) Cdc28 kinase activity regulates the basal transcription machinery at a subset of genes. Proceedings of the National Academy of Sciences (PNAS), in press

Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K, Hogendoorn PCW, Hovig, E, Myklebost;  O, Meza-Zepeda LA (2012) Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma. PLoS One PDF

KuijjerML, Rydbeck H, Kresse SH, Buddingh EP, Bürger H, Myklebost O, Hogendoorn PCW, Meza-Zepeda LA, Cleton-Jansen AM (2012) Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data Genes Chromosomes Cancer 51:696-706 PDF

Namløs H, Kresse SH, Müller CR, Henriksen J, Sæter G, Bruland Ø, Holdhus R, Bjerkehagen B, Steen VM , Myklebost O (2010) Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern Sarcoma  PDF

Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IHG, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O (2012) Modulation of the Osteosarcoma Expression Phenotype by MicroRNAs. PLoS One in press

Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza- Zepeda LA, Myklebost O(2012) Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma Cancer PDF

Reikvam DH, Derrien M, Islam R, Erofeev A, Grcic V, Sandvik A, Gaustad P, Meza-Zepeda LA, Jahnsen FL, Smidt H, Johansen FE (2012Epithelial-microbial crosstalk in polymeric Ig receptor deficient mice
Eur J Immunol, 42 (11), 2959-70 PubMed 22865203

Skotheim RI, Meza-Zepeda LA, Hovig E, Lønning PE, Lothe RA, Myklebost O  (2012) Genomsekvensering for persontilpasset kreftbehandling,  Tidsskr. Nor. Lægeforening 132:2406-8 PDF

See editorial on the above paper

Skårn M, Namløs HM, Noordhuis P, Meng-Yu Wang, Meza-Zepeda LA, Myklebost O (2012) Adipocyte Differentiation of Immortalized Human Bone Marrow-Derived Stromal Cells is Modulated by microRNA-155, microRNA-221 and microRNA-222 Stem Cells and Development  21:873-83 PDF

Stratford EW, Castro R, Daffinrud J, Skårn M, Lauvrak SU, Munthe E, Myklebost O (2012) Characterization of liposarcoma cell lines for preclinical and biological studies Sarcoma 2012 doi:10.1155/2012/148614 PDF

Thomas DM, Wilhelm M, Cleton-Jansen AM, Dirksen U, Entz-Werlé N, Gelderblom H, Hassan B, Jürgens H, Koster J, Kovar H, Lankester AC, Lewis IJ, Myklebost O, Nathrath MHM, Picci P, Whelan JS, Hogendoorn PCW, Bielack SS (2012) Workshop report on the European Bone Sarcoma Networking Meeting: integration of clinical trials with tumor biology. Journal of Adolescent and Young Adult Oncology Vol 1 In press PDF

Publications 2011

Buddingh EP, Kuijjer ML, Duim RAJ, Bürger H, Agelopoulos K, Myklebost O, Serra M, Hogendoorn PCW, Lankester AC, Cleton-Jansen AM (2011) Metastasis suppression by tumor-infiltrating macrophages in high-grade osteosarcoma. Clin Cancer Res 2011 17:2110-2119 PDF

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad Ø, Smeland S, Hovig E (2011) Potential therapeutic targets revealed by genome-wide screening of metastatic cells: Case report BMC Cancer 11:455 PDF 

Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A, Myklebost O (2011) Genomic validation of preclinical xenograft models of human sarcoma reveals recurrent loss of aberrations Cancer 118: 558–570 PDF Supplementary data

Kuijjer ML, Namlos HM, Hauben EI, Machado I, Kresse SH, Serra M, Llombart-Bosch A, Hogendoorn PCW, Meza-Zepeda LA, Myklebost O, Cleton-Jansen AM (2011) mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts BMC Medical Genomics, 4:66 PDF

Müller CR (2011) Novel approaches to the treatment of high-grade sarcoma. PhD Thesis, University of Oslo ISBN 978-82-8264-004-6 No 1112 PDF

Ohnstad HO, Paulsen EB, Noordhuis P, Berg M, Lothe RA, Vassilev L, Myklebost O (2011) Pharmacological interaction of the MDM2 antagnist Nutlin-3a and cytotoxic drugs in sarcoma cell lines BMC Cancer 11:211  PDF 

Stratford EW, Castro R, Wennerstrőm AB, Holm R, Munthe E, Lauvrak S, Bjerkehagen B, Myklebost O. Combined ALDH and CD133 expression defines a stem-like cancer cell population in liposarcoma xenograft Clin Sarcoma Res 1:8PDF